Nongonococcal Urethritis Medical Services in China

Non-gonococcal urethritis (NGU) in males is a common sexually transmitted infection characterized by urethral inflammation without evidence of *Neisseria gonorrhoeae*. It is most frequently caused by *Chlamydia trachomatis* and *Mycoplasma genitalium*, though other pathogens—including *Ureaplasma* species—may contribute. Symptoms typically include dysuria, urethral discharge, and urethral pruritus or irritation; however, up to 50% of cases may be asymptomatic, increasing the risk of complications such as epididymitis, prostatitis, or reactive arthritis if left untreated. Diagnosis relies on nucleic acid amplification tests (NAATs) targeting *C. trachomatis* and *M. genitalium*, often supplemented by urine-based PCR and culture where indicated. First-line therapy involves azithromycin or doxycycline, with tailored regimens for macrolide-resistant *M. genitalium* guided by molecular resistance testing.

China offers distinct advantages for NGU management: its urology and infectious disease specialists possess extensive clinical experience in complex and recurrent cases, supported by advanced molecular diagnostics—including next-generation sequencing for antimicrobial resistance profiling—and real-time therapeutic monitoring. Leading tertiary hospitals report >95% microbiological eradication rates in treatment-naïve patients and high resolution rates even in persistent or refractory presentations. Compared to Western countries, comprehensive diagnostic workup and targeted antimicrobial therapy cost approximately 40–60% less, with no compromise in evidence-based protocols or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access to these services—coordinating appointments with certified specialists, verifying transparent all-inclusive pricing, arranging visa support and accommodation, and providing multilingual care coordination from initial consultation through follow-up.

Treatment Options & Itemized Cost Breakdown: Non-Gonococcal Urethritis (Male)

Non-Surgical / Conservative / Medication Options

*Target Criteria:* Confirmed *Chlamydia trachomatis* or *Mycoplasma genitalium* infection via NAAT; mild-to-moderate symptoms (dysuria, urethral discharge); no treatment failure or resistance history.

• •First-Line Therapy (Tier 1 – Standard)

- Urine NAAT (Chlamydia/Mycoplasma): $28–$42 - Urinalysis + microscopy: $8–$12 - Total (meds + diagnostics): $65–$95

• •Second-Line Therapy (Tier 2 – Resistance Suspected/Confirmed)

- Confirmatory *M. genitalium* PCR + macrolide resistance testing (23S rRNA): $75–$110 - Liver function test (pre-moxifloxacin): $15–$22 - Total (meds + advanced diagnostics): $145–$210

• •Adjunctive Care

- Follow-up NAAT at 3 weeks (test-of-cure): $28–$42

Surgical / Procedural / Interventional Options

*Eligibility Criteria:* Chronic/recurrent NGU (>3 episodes/year) with documented persistent infection despite ≥2 guideline-concordant regimens *and* exclusion of reinfection (partner testing confirmed negative); evidence of urethral stricture on uroflowmetry/cystoscopy.

• •Diagnostic Cystourethroscopy (Pre-procedure workup required)

- Cystourethroscopy (flexible scope, outpatient): $180–$265 - Biopsy (if mucosal abnormality seen): $45–$68

• •Urethral Calibration/Dilation (for stricture-related NGU)

- OR operating room dilation under local anesthesia: $220–$330

Special / Complex Condition Options

• •Refractory NGU with *M. genitalium* fluoroquinolone resistance:

- Therapeutic drug monitoring (serum levels): $195–$285

• •HIV-coinfected patients: Enhanced monitoring (CD4/viral load + repeat NAAT): +$135–$200

Quick Selection Guide

• •Young adult (<35), first episode, budget <$100: Tier 1 therapy ($65–$95) — optimal efficacy, minimal cost.
• •Age >45, recurrent NGU, comorbid diabetes/hypertension: Tier 2 + LFT ($145–$210) — avoids doxycycline GI risks and ensures resistance detection.
• •Chronic NGU (>1 year), failed 3 regimens, suspected stricture: Cystourethroscopy ($180–$265) + calibration ($85–$125) — targets structural contributor.
• •HIV+ or immunocompromised: Full Tier 2 + HIV-specific monitoring ($280–$410) — prevents complications from delayed clearance.